https://doi.org/10.4081/mm.2022.10405
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

Authors

Giuseppina Amarù
S.C. Laboratorio Analisi Unificato Rivoli-Pinerolo ASL TO3, Rivoli (TO), Italy.
Lara Scoppapietra
S.C. Laboratorio Analisi Unificato Rivoli-Pinerolo ASL TO3, Rivoli (TO), Italy.
Cristina Crocillà
S.C. Banca del Sangue e Immunoematologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Italy.
Marika Salafia
S.C. Banca del Sangue e Immunoematologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Italy.
Mara Finotti
S.C. Banca del Sangue e Immunoematologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Italy.
Vittorio Schiavo
S.C. Banca del Sangue e Immunoematologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Italy.
Valentino Granero
vgranero@cittadellasalute.to.it
S.C. Banca del Sangue e Immunoematologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Italy.

Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria. This combination is chosen as an alternative in infections caused by Gram-negative bacteria when carbapenem-only therapies are unsatisfactory.

Materials and methods: Based on this, we report our assessment of such meropenem/vaborbactam association through the E-test and the Microscan routine automated system. This evaluation was performed on 22 samples, carbapenem-resistant strains of Gram-negative bacteria isolated from different types of biological material. Five E. coli and 1 P. mirabilis were respectively susceptible to both carbapenems and Mer/Vab, 6 P. aeruginosa and 2 A. baumannii were respectively resistant to both carbapenems and Mer/Vab and out of 8 K. pneumoniae which were resistant to carbapenems only one was resistant to the Mer/Var combination.

Results and conclusions: From the data obtained, it can be seen that resistance to carbapenems is 72%, and drops to 36% with the combined use of Mer/Vab. However, this combination cannot be used in the treatment of patients with diseases caused by P. aeruginosa and Acinetobacter spp., resistant to meropenem.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
0
Scopus
0
Google Scholar
Europe PMC
Bradley N., Lee Y. Practical Implications of New Antibiotic Agents for the Treatment of Carbapenem-Resistant Enterobacteriaceae. Microbiol Insights 2019;12:e-Collection 2019. DOI: https://doi.org/10.1177/1178636119840367
Dhillon S. Meropenem/vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs 2018;78:1259-1270. DOI: https://doi.org/10.1007/s40265-018-0966-7
European Medicines Agency. Vabomere (meropenem / vaborbactam) 657766/2018. Available at: https://www.ema.europa.eu/en/documents/overview/vabomere-epar-medicine-overview_it.pdf (last access on January the 11th, 2022).
Johnston BD, Thuras P, Porter SB, et al. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J Glob Antimicrob Resist 2021;24:190-197. DOI: https://doi.org/10.1016/j.jgar.2020.12.017
Kinn PM, Chen DJ, Chiring DM, et al. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagn Microbiol Infect Dis. 2019;93:258-260. DOI: https://doi.org/10.1016/j.diagmicrobio.2018.09.017
Kufel WD, Eranki AP, Paolino KM, et al. In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis. J Antimicrob Chemother 2019;7:2117-2118. DOI: https://doi.org/10.1093/jac/dkz103
Parisio EM. [Le nuove molecole antibiotiche per il trattamento delle infezioni da batteri gram-negativi.][Article in Italian.] Infection Control. October the 25th, 2021. Azienda USL Toscana Nord Ovest, Italy.
Vaccaro E. [Polmoniti e altre infezioni da batteri Gram negativi, il corretto place in therapy dei nuovi farmaci.][Article in Italian.] #SIMIT2020. January the 13th, 2021.

Supporting Agencies

None

How to Cite

Amarù, G., Scoppapietra, L., Crocillà, C., Salafia, M., Finotti, M., Schiavo, V., & Granero, V. (2022). Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital. Microbiologia Medica, 37(1). https://doi.org/10.4081/mm.2022.10405

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.